Journal of Clinical and Experimental Investigations

Abstract

Objectives: Obstructive sleep apnea syndrome (OSAS) which is characterized by recurrent pharyngeal narrowing and breathing disturbances, can affect central neural system (CNS). S100B, which exerts neurotrophic and gliotrophic features, is a calcium binding protein. The aim of this study was to evaluate serum levels of S100B in patients with OSAS.
Materials and methods: Clinical and laboratory assessment were performed in 26 patients (5 women and 21 men) with OSAS and 28 (8 women and 20 men) age-, body mass index (BMI)- and sex- matched healthy subjects served as controls . The patients included in the study had whole-night polysomnography (PSG) performed in the sleep laboratory. Measurements of S100B were done using the commercially available ELISA kit.
Results: Patients and controls were well matched with regard to demographic characteristics. Serum S100B concentrations were 149.4±84.5 ng/L and 139.2±70.7 ng/L for patients with OSAS and control subject, respectively. There was no statistically significant difference in serum S100B concentrations between OSAS and control groups (p>0.05).
Conclusions: Serum S100B protein level in serum did not significantly higher in patients with OSAS compared to the healthy subjects. However, further investigations are required, particularly in the area of biochemical markers of mild cerebral damage in patients with OSAS.